Semaglutide shows potential anti-aging and heart benefits in new studies

Research led by UC Berkeley suggests that semaglutide, a GLP-1 receptor agonist used for diabetes and weight loss, may have anti-aging properties. In laboratory studies, aged mice treated with semaglutide showed improved muscle and cognitive performance, reduced inflammatory pathways, and an extended median lifespan by nearly 100 days. Researchers noted that these benefits appeared to operate through biological pathways independent of caloric restriction.

Beyond aging, semaglutide has demonstrated significant cardiovascular benefits. A mediation analysis of the SELECT trial found that while improvements in weight, blood pressure, and cholesterol explain about 31.4% of the drug's reduction in major adverse cardiovascular events, a large portion of the cardioprotective effect remains unexplained, potentially involving unidentified anti-inflammatory or vascular mechanisms.

As the use of GLP-1 medications surges globally, medical professionals are highlighting the importance of clinical supervision. Experts warn against using these drugs as a quick fix for cosmetic weight loss, noting that they require specific medical indications and can cause side effects such as gastrointestinal issues and temporary hair loss (telogen effluvium). Emerging discussions also include the potential for microdosing these medications to manage metabolic shifts during perimenopause.